Completed PHASE4 INTERVENTIONAL NCT00400582

A Pharmacogenomic Study of Candesartan in Heart Failure

Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms

Sponsor: AstraZeneca

Conditions Heart Failure

Interventions Candesartan up to 32 mg daily

Updated 6 times since 2017 Last updated: Jul 20, 2011 Started: Nov 30, 2006 Primary completion: Apr 30, 2010 Completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Heart Failure, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2006. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Montreal Heart Institute

Data source: Montreal Heart Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada